June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

January 10, 2017

Otezla Improves Psoriatic Arthritis Symptoms, Study Shows

News

Long-term use of Celgene‘s treatment Otezla (apremilast) has improved psoriatic-arthritis patients’ symptoms, according to a study. The improvements included less psoriasis, lower swollen and tender joint counts, less enthesitis — or inflammation where ... Read more

January 5, 2017

Licensing Deal Worth $790M Reached For Potential Psoriasis Treatment, AST-005

News

Purdue Pharma and Exicure have announced a strategic research alliance and licensing agreement for AST-005, a potential treatment for psoriasis and other diseases amenable to a gene regulation approach by Exicure ... Read more

January 3, 2017

Scientists Identify Molecules that Link Psoriasis and Heart Disease

News

Researchers have identified novel molecular pathways leading to inflammation in psoriasis that also can trigger heart failure in patients, according to results from two studies undertaken at Case Western Reserve ... Read more

December 22, 2016December 22, 2016

Psoriasis Foundation Issues Treatment Goals to Help Patients Judge a Therapy’s Benefit

News

A consortium led by the National Psoriasis Foundation (NPF) Medical Board has established treatment goals for patients with psoriasis, including detailed information on how long it should take for patients ... Read more

December 20, 2016

Stelara May Block Protein That Fights Psoriasis, Study Says

News

Stelara (ustekinumab), an FDA-approved antibody treatment for psoriasis, may also inhibit a protein that fights the disease, according to new research. A University of Zurich team led by Burkhard Becher conducted ... Read more

December 15, 2016

Phase 2 Study of Oral Treatment for Plaque Psoriasis, LYC-30937-EC, Starts in US

News

Lycera announced the start of a Phase 2 clinical trial testing its lead candidate, LYC-30937-Enteric Coated, as an oral treatment for moderate chronic plaque psoriasis. The randomized, placebo-controlled and double-blind study, called UPRISE (NCT02872285), will ... Read more

December 8, 2016December 8, 2016

Phase 3 Trials Show Response to Xeljanz in People with Active Psoriatic Arthritis

News

Pfizer presented positive results from its Phase 3 OPAL clinical program evaluating the effectiveness and safety of Xeljanz (tofacitinib citrate) in adult patients with active psoriatic arthritis (PsA), who had an inadequate ... Read more

December 6, 2016

Novan’s Nitric Oxide-Releasing Therapy Candidate Shows Positive Results for Psoriasis

News

Novan, Inc. recently announced positive results of the company’s preclinical study investigating the efficacy of its lead nitric oxide-releasing candidate, SB414, in treating psoriasis. Nitric oxide is a gas that ... Read more

December 1, 2016

Psoriatic Arthritis Often Misunderstood and Difficult to Diagnose, Survey Finds

News

Results from Psoriatic Arthritis In America 2016, a new U.S. survey of more than 500 people with psoriatic arthritis (PsA), reveal that securing a diagnosis often is a lengthy and frustrating ordeal, with most patients ... Read more

November 30, 2016December 13, 2016

Sirbal Receives EU Clearance to Market Herbal Cosmetic Skin Cream for Psoriasis

News

Sirbal has received a provisional safety report for its SIRB-001 cream, a multi-herbal extract of Chinese herbs under development for multiple dermatological indications, including psoriasis, scalp psoriasis, atopic dermatitis, eczema, ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata